Current status of CPT and its analogues in the treatment of malignancies

  title={Current status of CPT and its analogues in the treatment of malignancies},
  author={Guohua Hu and David Zekria and Xun Cai and Xiaoling Ni},
  journal={Phytochemistry Reviews},
Camptothecin (CPT) is a kind of terpene indole alkaloid which was firstly isolated from native Chinese happy tree Camptotheca acuminata and owns a unique anti-tumor mechanism by inhibiting Topo I. Being approved by FDA, the camptothecin derivatives, irinotecan and topotecan, are extensively used for the treatment of various cancers throughout the world. In the past decades, pharmacology of CPT and its analogues has been well documented. This review will focus on different human malignancies… Expand
Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents
Preliminary in vivo results indicated a strong antitumor activity on human mesothelioma primary cell line MM473 orthotopically xenografted in CD-1 nude mice and very high tolerability. Expand
Synthesis and antitumor activity of pyrano[3,2-i]-fused camptothecin derivatives
A novel series of A-ring modified hexacyclic camptothecin derivatives containing a pyranone ring fused at the 9-positions and 10-positions were designed and synthesized. These new derivatives wereExpand
Effect of Pterostilbene, a Natural Derivative of Resveratrol, in the Treatment of Colorectal Cancer through Top1/Tdp1-Mediated DNA Repair Pathway
  • Yutian Zhang, Ying Li, +6 authors Di Zhao
  • Medicine
  • Cancers
  • 2021
Overall, PTE and RE can inhibit the activity of Top1 enzyme and inhibit the DNA damage repair pathway mediated by Top1/Tdp1, and can effectively inhibit colorectal cancer development with low toxicity, thus they have great potential to be developed into a new generation of anti-tumor drugs. Expand
Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I.
The replacement of the potentially genotoxic 3-nitro group by 3-chloro and 3-fluoro substituents is documents, resulting in compounds with high Top1 inhibitory activities and potent cytotoxicities in human cancer cell cultures and reduced lethality in an animal model. Expand
Synthesis, characterization, and in vitro SAR evaluation of N,N'-bis(arylmethyl)-C2-alkyl substituted imidazolium salts.
Several derivatives of C2-alkyl substituted N,N'-bis(arylmethyl)imidazolium salts have high aqueous solubilities with potent anti-proliferative properties and are ideal candidates for future in vivo xenograft studies and have high potential to progress into clinic use. Expand
Redox-sensitive dimeric camptothecin phosphatidylcholines-based liposomes for improved anticancer efficacy.
In vitro and in vivo anticancer assay showed the enhanced efficacy of CPT-SS-GPCs liposomes, which have great potential in tumor therapy. Expand
Benzothiopyranoindole- and pyridothiopyranoindole-based antiproliferative agents targeting topoisomerases.
New benzothiopyranoindoles (5a-l) and pyridothiopyranoindoles (5m-t), featuring different combinations of substituents (H, Cl, OCH3) at R2-R4 positions and protonatable R1-dialkylaminoalkyl chains,Expand
Phytochemicals in medicine and food
  • J. Xiao
  • Biology
  • Phytochemistry Reviews
  • 2015
The international organizing committee and scientific advisory board of ISPMF2015 assembled an exciting and diverse program, featuring 10 keynote lectures, 24 invited lectures, 50 short lectures, and about 130 posters, which dedicate to creating a stage for exchanging the latest research results in the phytochemicals for food and human health. Expand


Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer
This phase II study was designed to evaluate the toxicity and efficacy of belotecan combined with carboplatin in patients with recurrent epithelial ovarian cancer (EOC). Expand
Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
  • G. Pratesi, M. de Cesare, +9 authors F. Zunino
  • Biology, Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2002
The unusual potency of ST1481 in a variety of tumor cell lines suggests the ability of the drug to overcome several resistance factors and further supports the therapeutic interest in the novel analogue. Expand
In vivo antitumor and antimetastatic activities of camptothecin encapsulated with N-trimethyl chitosan in a preclinical mouse model of liver cancer.
CPT-TMC effectively inhibited tumor growth and lymphatic metastasis, prolonged survival time, yet without apparent toxic effects and may provide a novel and effective therapeutic strategy against human advanced hepatic cancer without conspicuous systemic toxic effects. Expand
Preclinical Results of Camptothecin-Polymer Conjugate (IT-101) in Multiple Human Lymphoma Xenograft Models
The promising present results provide the basis for a phase I clinical trial in patients with relapsed/refractory lymphoma, and the in vitro cytotoxicity of IT-101, CPT-11, and their metabolites against multiple human lymphoma cell lines is determined. Expand
Activity of 9‐nitro‐camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia
9‐Nitro‐camptothecin (9‐NC) is a new oral topoisomerase inhibitor with a good safety profile evaluated in MDS and CMML. Expand
The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.
It is shown that, despite the lowest intracellular accumulation, gimatecan was the most active among the camptothecin analogues studied, and it is proposed that DNA strand breaks efficiency as measured by the Comet assay might provide important information about the stability of the ternary complexes induced by campthecin compounds. Expand
Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy‐naive patients with extensive‐disease small cell lung cancer
The objective of this study was to investigate the efficacy of belotecan, a new camptothecin analog, combined with cisplatin for the treatment of chemotherapy‐naive patients with extensive‐diseaseExpand
Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.
Gimatecan was significantly more effective than topotecan in inhibiting the growth of HT1376 tumor, thus reflecting antiproliferative potency and providing additional insights into the cellular basis of drug potency. Expand
Camptothecin nanocolloids based on N,N,N-trimethyl chitosan: Efficient suppression of growth of multiple myeloma in a murine model
It is suggested that N,N,N-trimethyl chitosan could increase the stability and the antitumor effect of CPT and CPT-TMC is a potential approach for the effective treatment of multiple myeloma. Expand
A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.
The results suggest that belotecan is relatively active and well tolerated as a second-line agent in patients with SCLC. Expand